Please use this identifier to cite or link to this item: http://repository.i3l.ac.id/jspui/handle/123456789/281
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRamanto, Kevin Nathanael-
dc.date.accessioned2022-03-25T09:08:28Z-
dc.date.available2022-03-25T09:08:28Z-
dc.date.issued2020-09-28-
dc.identifier.urihttp://repository.i3l.ac.id/jspui/handle/123456789/281-
dc.description.abstractThe development of antimalaria vaccines hindered by genetic diversity that possessed by Plasmodium sp., which makes the proposed antigen have a low efficacy towards non-vaccine strain. Previously, we have shown P41, P48/45, and P230 protein from 6-Cysteine shared by Plasmodium sp. and could be used for cross-species antimalaria vaccines. Two different approaches are known as ancestral, and consensus sequence reconstruction were used in this study to validate the efficacy of P41, P48/45, and P230 as cross-species vaccine candidate. Phylogenetic and time tree reconstruction was conducted to determine the relationship of 6-Cysteine proteins and help the sequence reconstruction. The structural prediction was made by using the psipred and Rosetta program. The characteristic of proteins was analyzed by assessing hydrophobicity, Post-Translational Modification sites, and molecular docking simulation. Meanwhile, the immunogenicity score for B-cell, T-cell, and MHC was determined using an immunoinformatic approach. The result suggests that ancestral sequences are more stable with a higher number of epitopes. The conserved epitopes between ancestral and consensus which consist of specific modifications and located in binding sites were located in all target proteins. The presence of conserved epitopes might indicating greater efficacy possess by 6-Cysteine proteins. Thus, this study provides detailed insight into P41, P48/45, and P230 efficacy for the cross-species antimalaria vaccine.en_US
dc.language.isoenen_US
dc.publisherIndonesia International Institute for Life Sciencesen_US
dc.relation.ispartofseriesBI 20-003;T202010011-
dc.subjectmalariaen_US
dc.subjectVaccine Developmenten_US
dc.subject6-Cysteineen_US
dc.subjectprotein structureen_US
dc.subjectImmunogenicityen_US
dc.titleStructural and Immunogenicity Analysis of P41, P48/45, and P230 Protein of Plasmodium sp. as a Potential Vaccine Target Candidate Against Malaria Infectionen_US
dc.typeThesisen_US
Appears in Collections:Bioinformatics

Files in This Item:
File Description SizeFormat 
T202010011_BI_Kevin Nathanael R.pdf
  Restricted Access
Full text15.99 MBAdobe PDFView/Open Request a copy
Cover.pdfCover143.08 kBAdobe PDFView/Open
Abstract.pdfAbstract88.38 kBAdobe PDFView/Open
Chapter 1.pdfChapter 1125.47 kBAdobe PDFView/Open
References.pdfReferences4.5 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.